A Japanese pharmaceutical firm Shionogi & Co Ltd has claimed that its Covid pill has shown rapid clearance of the virus that causes COVID-19.
The pill, S-217622, "demonstrated rapid clearance of the infectious SARS-CoV-2 virus", Shionogi said in a statement on Sunday, citing Phase-2b results from the Phase II/III clinical trial of the drug.
READ | France elections: Emmanuel Macron wins second term, defeats far-right rival Marine Le Pen
The company has global aspirations for the antiviral pill, which is now being evaluated by Japanese regulators.
The findings released on Sunday also showed "there was no significant difference in total score of 12 COVID-19 symptoms between treatment arms" although the drug showed improvement in a composite score of five "respiratory and feverish" symptoms, Shionogi said.
The drugmaker said in March it would launch a global Phase III trial worldwide for the drug with US government support, and Chief Executive Isao Teshirogi has said production could reach 10 million doses a year.
Shionogi`s shares have been on a rollercoaster on speculation about the success of the treatment. The stock climbed on Friday after a report the U.S. government is in talks to acquire supplies of the drug.
.
READ | Covid 4th wave: Amid China’s stringent censorship, Shanghai residents vent their anger online
On April 13 the stock sank by as much as 16% on reports the drug could pose risks to pregnancies, based on preclinical data.
(With Reuters inputs)
